The use of bacteria, specifically probiotic bacteria, to support the mucus membranes—especially those lining the respiratory, gastrointestinal, and urogenital tracts—is supported by scientific evidence. Mucus membranes serve as a primary barrier against pathogens, and their health is closely linked to the balance of the microbial communities that reside on or near these surfaces. Numerous clinical and laboratory studies indicate that certain probiotic strains (such as Lactobacillus and Bifidobacterium species) can enhance the integrity and function of mucus membranes by modulating immune responses, promoting mucus production, and competing with pathogenic microbes for adhesion sites.

For example, randomized controlled trials have shown that probiotics can reduce the incidence and severity of infections in the respiratory and gastrointestinal tracts, which are lined by mucus membranes. The mechanisms proposed include increased production of protective mucins, strengthening of tight junctions, and modulation of local immune activity. Reviews published in journals like Frontiers in Microbiology and Nutrients have summarized this evidence, concluding that specific probiotics can support mucosal barrier function and resilience. However, the effects are strain-specific; not all bacteria have these benefits, and not all studies show positive results.

In summary, there is a moderate to strong scientific basis for the use of certain probiotic bacteria to support mucus membrane health, but the benefits depend on the strains used and the target body site.